About 1,306,158 results

Ruxolitinib Cream Quickly Addresses Itch in Atopic Dermatitis
Dermatology Advisor

Sep 30th, 2022 - Ruxolitinib cream was associated with rapid improvement in itch in patients with mild to moderate atopic dermatitis (AD) and was sustained for 8 weeks, according to study findings published in the Journal of the European Academy of Dermatology and Venereology. Investigators reported their findings regarding the timing and extent of the effect of ruxolitinib cream on itch in patients with AD usi...

Focus on Cardiometabolic Disease Risk in Psoriatic Arthritis – With Brittany Weber, MD
Rheumatology Advisor

Sep 30th, 2022 - Patients with vs without psoriatic arthritis (PsA) have markedly elevated risks to their cardiometabolic health. More than half of patients with PsA have at least 1 comorbidity (Figure 1).1 Patients with PsA are estimated to be 46% more likely to be diagnosed with a cardiovascular disease (CVD) than the general population, with a higher rate of hospitalization related to CVD as well.2 Moreover,...

Left Atrial Reservoir Strain May Predict Atrial Fibrillation After STEMI
Cardiology Advisor

Sep 30th, 2022 - Left atrial (LA) reservoir strain is an independent predictor of incident atrial fibrillation (AF) after an ST-segment elevation myocardial infarction (STEMI) and primary percutaneous coronary intervention (pPCI), according to a study in the International Journal of Cardiology. Investigators sought to determine the prognostic value of LA strain measured via 2-dimensional speckle tracking echoca...

Symptom Duration After COVID-19 Onset Studied in Autoimmune Rheumatic Diseases
Rheumatology Advisor

Sep 30th, 2022 - Prolonged COVID-19 symptom duration was assessed in patients with systemic autoimmune rheumatic diseases (SARDs), in a study published in RMD Open. While the majority of patients with SARDs had complete symptom resolution by day 15 after COVID-19 onset, some reported symptoms that persisted for at least 28 days, with 1 in 10 experiencing symptoms for at least 90 days. Researchers analyzed data ...

Extended-Release Subcutaneous Bupivacaine May Provide Analgesia Up to 96 Hours
Rheumatology Advisor

Sep 30th, 2022 - Peri-incisional subcutaneous (SC) injection of 4% bupivacaine appeared to reduce incisional pain and had no evidence of local toxicity, according to results of an animal model study published in Pain Medicine. The analgesic efficacy of an injectable hydrogel carrier (poly[N-isopropylacrylamide-co-dimethylbutyrolactone acrylamide-co-Jeffamine M-1000 acrylamide]) containing 4% bupivacaine (SBG004...

Neurological vs Psychiatric Outcomes After COVID-19: Which Risks Last Longer?
Dermatology Advisor

Sep 30th, 2022 - Following COVID-19 infection, the risk for developing neurological disorders remains high after 2 years, while the risk for psychiatric disorders subsides earlier. These are the findings of a study published in Lancet Psychiatry. Researchers analyzed outcome data in a multinational, retrospective cohort study. They obtained data from the TriNetX electronic health records network between January...

Tecovirimat Shown to Alleviate Severe Proctitis in Patients With Monkeypox
Rheumatology Advisor

Sep 30th, 2022 - Tecovirimat is well tolerated and associated with the rapid alleviation of rectal pain among patients with severe proctitis secondary to monkeypox virus, according to case report findings published in Annals of Internal Medicine. In this case report, the study authors described the effects of oral tecovirimat for the treatment of monkeypox virus-associated severe proctitis in 2 men, both of who...

Vaccination Status May Affect Venous Thromboembolism Risk in Ambulatory COVID-19
Cardiology Advisor

Sep 30th, 2022 - Ambulatory COVID-19 is associated with a substantial increase in excess venous thromboembolism (VTE), which is substantially higher among unvaccinated individuals, and increases with older age, in men, and in patients with obesity. These are the findings of a retrospective study published in JAMA Internal Medicine. Researchers conducted a population-based cohort study to explore the clinical an...

Anticentromere Antibodies Can Serve as Diagnostic Marker for Sjögren Syndrome
Dermatology Advisor

Sep 30th, 2022 - Anticentromere antibodies (ACAs) can serve as a diagnostic serologic marker for Sjögren syndrome, and patients with ACA-positivity should be examined for Sjögren syndrome, noted the authors of a study published in Journal of Oral Science. Recent reports have shown that some individuals with ACA positivity exhibit xerophthalmia (dry eyes) and xerostomia (dry mouth), both of which are characteris...

Dupixent Approved for Adults With Prurigo Nodularis
Dermatology Advisor

Sep 30th, 2022 - The Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with prurigo nodularis. The approval was based on data from the 24-week randomized, double-blind, placebo-controlled, parallel-group phase 3 PRIME (ClinicalTrials.gov identifier: NCT04183335) and PRIME2 (ClinicalTrials.gov identifier: NCT04202679) trials, which assessed the efficacy and...

OSA Is Prevalent in Pulmonary Hypertension, Especially in WHO Group II PH
Cardiology Advisor

Sep 30th, 2022 - Obstructive sleep apnea (OSA) is common in all patients with pulmonary hypertension (PH) and is especially prevalent and severe in those with PH due to left-sided heart disease — categorized by the World Health Organization (WHO) as having group II PH – who experience a median of 12 sleep events per hour. These are among study findings published in BMJ Open Respiratory Research. Comorbid OSA is...

AGA Clinical Practice Update: Expert review of management of refractory celiac disease
Carolyn Crist

Sep 30th, 2022 - The diagnosis and management of refractory celiac disease remains challenging, but ongoing studies can provide the proper diagnostic criteria and identify the optimal management strategies, according to a new American Gastroenterological Association expert review published in Gastroenterology. Celiac disease is present in about 1% of the U.

LivaNova (TandemLife) Recalls LifeSPARC System for Risk of Unintentional Extended Pump ...
MedWatch; FDA

Sep 30th, 2022 - The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. The LifeSPARC System is intended to pump the blood through an extracorporeal circuit for periods lasting less than 6 hours for the purpose of providing either: The LifeSPARC System has two components: the LifeSPARC Pump and the LifeSPARC Controller. The Lif...

2022 Medical Device Recalls
MedWatch; FDA

Sep 30th, 2022 - The list below contains recalls that were issued in 2022.

‘Love hormone’ revealed to have heart healing properties

Sep 30th, 2022 - The neurohormone oxytocin is well-known for promoting social bonds and generating pleasurable feelings, for example from art, exercise, or sex. But the hormone has many other functions, such as the regulation of lactation and uterine contractions in females, and the regulation of ejaculation, sperm transport, and testosterone production in males. Now, researchers from Michigan State University ...

Health Data Research UK’s Better Care program announces recommendations for developing learning health systems in the UK

Sep 30th, 2022 - Researchers are calling on policy makers to support the use of data-driven learning health systems to deliver a step change in the NHS's ability to improve patient care. The call comes as a new report, authored by the Better Care programme from Health Data Research UK (HDR UK) and the Health Foundation, warns that tackling the huge pressures currently faced by health and care services as a resu...

Advanced and Metastatic Non-Small Cell Lung Cancer: How a Proper Clinical Sensibility Emerges from Accumulated Experience

Sep 30th, 2022 - Jared Weiss, MD, implores clinicians to ask "what else?" to dig a little deeper when encountering patients with non–small cell lung cancer (NSCLC) and move away from the idea of an epiphany produced by a single diagnosis. Dr Weiss uses a patient experience to illustrate this point. A young patient was diagnosed with squamous lung cancer, an atypical diagnosis for a "never-smoker." Dr Weiss dug ...

Ventricular Arrhythmia Clinical Practice Guidelines (ESC, 2022)

Sep 30th, 2022 - Updated clinical guidelines for managing patients with ventricular arrhythmias and preventing sudden cardiac death were published in August 2022 by the European Society of Cardiology (ESC), in the European Heart Journal.[1] In patients presenting with tolerated sustained monomorphic ventricular tachycardia (SMVT), first-line treatment with direct current cardioversion is recommended if the anes...

The Future of Epidemics; A New Dementia Prognosis Tool; Physician Burnout Is Reaching Alarming Levels

Sep 30th, 2022 - The Future of Epidemics It seems like one epidemic after another is in the news these days. But are there really more of them? Short answer: yes. Emerging, reemerging diseases: Some diseases have appeared in recent years for the first time; some are old ones that are resurging. New vectors include SARS-CoV-1, SARS-CoV-2, and H1N1. Transmitted from animals to humans, these viruses initially appe...

Has COVID Swayed the Rise in Pneumococcal Disease in Spain?

Sep 30th, 2022 - Before COVID-19 vaccines were widely available, one of the most common and serious manifestations of SARS-CoV-2 infection was pneumonia. Therefore, it is logical to ask whether the COVID-19 pandemic has played a role in the increase in Spain in the number of cases of pneumococcal disease caused by antibiotic-resistant strains. The instinctual response is that there should be no relationship, si...